6 results about "Serum specimen" patented technology

The invention discloses a coater for clinical treponema pallidum non-specific antibody detection test. The coater comprises a main body hollow handle, a rubber coating sleeve and a standby liquid injector, wherein the main body hollow handle comprises a handle body, a handle piston rod, a liquid injection port and a main body needle head; the rubber smearing sleeve is integrally formed and comprises an outer wrapping connector and a smearing wafer. And the liquid injection part comprises an independent standby injector. The coater can store liquid, is large and uniform in coating surface and convenient to operate, the liquid outlet amount is convenient to adjust due to piston type liquid outlet, the needle head, the coating wafer and the like can be replaced, the problem of coating a serum specimen is effectively solved, and the coater is used for coating a treponema pallidum non-specific antibody detection test specimen.

The present application relates to a specimen extraction solution and a specimen extraction method, and an inspection reagent using the same, the specimen extraction solution containing a component capable of inhibiting false negative reactions that cannot be completely inhibited by conventional methods when detecting antigens such as viruses, bacteria, and proteins to be detected from specimens from body fluids such as a nasal swab specimen, a nasal aspirate specimen, a nasal lavage specimen, a nasal discharge specimen, a throat swab specimen, a saliva specimen, a fecal specimen, a serum specimen, a plasma specimen, a urine specimen, and the like using an inspection reagent that utilizes antigen-antibody reactions or reactions of substances having interactions with each other. The specimen extraction solution of the inspection reagent, or a component that comes into contact with a specimen in a process before a detection reaction of a detection object or a process performed simultaneously with the detection reaction, and the like contain a water-soluble compound having a phenyl group, a benzyl group, a tolyl group, or a xylyl group in the structure, and at least a functional group including a carboxyl group or a carboxyl group methylated or ethylated atom group or a hydroxyl group bonded to the above group.

The utility model discloses a subpackage freezing storage device for serum specimens, which relates to the technical field of medical equipment and comprises a subpackage tube, a subpackage seat and a thawing extrusion seat, the subpackage tube is of a square column-shaped structure with square ribs fixedly connected to the centers of two sides, a round through hole is formed in the center of the subpackage tube, and the round through hole is communicated with the subpackage seat. The bottom of a round through hole of the split charging pipe is fixedly connected with a split charging needle-threading rubber plug, the split charging pipe can be used for split charging and storing blood samples, the split charging seat can be matched with the split charging pipe through the split charging seat, uniform split charging of the serum samples is achieved, whole freezing storage is achieved, only the split charging seat needs to be labeled, distinguishing and finding are convenient, and the split charging efficiency is improved. By means of the arranged thawing extrusion base, the thawing extrusion base can be matched with the split charging pipe, thawing of serum can be accelerated, transfer and detection of the serum can be achieved without transferring the serum to a PCR pipe, multiple sets of operation can be conducted at the same time, and the operation steps of serum sample detection are greatly reduced.

The present invention discloses a kit for quantitatively detecting serum autoantibodies in gastric cancer and precancerous lesions and its application. The kit includes a solid-phase carrier, a recombinant antigen protein coated on the solid-phase carrier, an enzyme-labeled secondary antibody, a standard product, a chromogenic substrate, a washing solution, and a reaction termination solution. This detection kit can specifically and quantitatively detect the levels of RAE1, PGK1, and NPM1 autoantibodies in serum specimens, and is significantly superior to the currently clinically used serum markers CEA and CA19-9 in terms of sensitivity for early screening and diagnosis of gastric cancer and precancerous lesions.

The application provides an automatic reading method and system for antibody identification results based on a vector space model, which comprises the following steps: constructing an antibody specificity vector model, mapping the antigen spectrum corresponding to each antibody specificity in an antibody identification pedigree table into an antibody specificity vector with a fixed dimension; mapping the reaction results of antibody identification of a serum sample to be tested into a to-be-tested vector through the antibody specificity vector model; calculating the similarity between the to-be-tested vector and the antibody specificity vector; and performing reading based on reading logic according to the similarity calculation results to obtain antibody identification results. The antibody identification results can be automatically read by calculating the vector similarity, the antibody identification can be realized quickly, accurately and standardly, and the work efficiency is improved significantly, and the manpower is liberated.

The application belongs to the technical field of biological medicine, discloses application of bone metastasis specific secreted protein DKK3 in early diagnosis of lung cancer bone metastasis, and specifically discloses application of a substance for detecting DKK3 in preparation of a product for diagnosing or early screening of lung cancer bone metastasis. The application discloses the relationship between secreted protein DKK3 expression and lung cancer specific bone metastasis for the first time, and verifies that secreted protein DKK3 is specifically highly expressed in serum samples of lung cancer bone metastasis patients and lung cancer bone metastasis cells, which indicates that secreted protein DKK3 can be used as a new lung cancer bone metastasis diagnostic marker, and can significantly distinguish lung cancer patients with bone metastasis from lung cancer patients with metastasis to other organs and healthy people.